SCHEMBL15375495

SCHEMBL15375495

CNC(=O)C(O)c1ccccc1COc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 1/20 0.43
PTPRC P08575 1/20 0.43
PTPN1 P18031 1/20 0.43
KCNH2 Q12809 1/20 0.42
LTA4H P09960 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CAPN1 P07384 1/20 0.41
MAOB P27338 3/20 0.40
NR4A2 P43354 1/20 0.40
USP2 O75604 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
FABP4 P15090 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15401828 0.91 MEN1 (0.46) MEN1KMT2APTPRCPTPN1KCNH2
SCHEMBL15401872 0.88 RXRA (0.44) MEN1KMT2AKDM4EKCNH2LTA4H
SCHEMBL15402278 0.88 RAB9A (0.45) MEN1KMT2AKDM4EKCNH2LTA4H
SCHEMBL15401870 0.87 POLB (0.44) MEN1KMT2ASMN1; SMN2KDM4EKCNH2
SCHEMBL15402063 0.87 KMT2A (0.45) MEN1KMT2ASMN1; SMN2MAOB
SCHEMBL15401611 0.87 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2KDM4EKCNH2
SCHEMBL15401831 0.87 MAOB (0.40) MEN1KMT2AKCNH2ALDH1A1MAOB
SCHEMBL15375596 0.84 LTA4H (0.46) KMT2ASMN1; SMN2KDM4EPTPRCPTPN1
SCHEMBL1190785 0.84 PRMT5 (0.38) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL27940488 0.83 KCNH2 (0.35) MEN1KMT2APTPRCPTPN1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
CN-103641731-B The manufacture method of phenylacetyl amine compound SUMITOMO CHEMICAL CO., LTD. (JP) 2015-10-28 CN disclosed
CN-103588657-A Method for producing phenylacetamide compound SUMITOMO CHEMICAL CO 2014-02-19 CN disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
CN-102348677-A Method for producing phenylacetamide compound SUMITOMO CHEMICAL CO 2012-02-08 CN disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA MEN1 4702/4885KMT2A 777/4885SMN1; SMN2 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.